CLPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ClearPoint Neuro (CLPT) is not a strong buy at the moment for a beginner, long-term investor. The stock has shown a recent downtrend in price, with technical indicators signaling bearish momentum. While the company has demonstrated strong revenue growth and has significant partnerships under FDA expedited review, the lowered guidance for 2026 and lack of immediate positive trading signals suggest waiting for more stability or a clearer upward trend before investing.
The stock is in a bearish trend with the MACD histogram below 0 and negatively expanding. RSI is at 26.404, indicating oversold conditions but not providing a clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level of 9.387, with resistance at 10.529.
Strong Q4 2025 revenue growth of 33.96% YoY. 13 partners under FDA expedited review with potential approvals. Commercial gene therapy thesis appears de-risked with meaningful upside optionality.
Lowered 2026 revenue guidance due to removal of certain partner revenue and reset of European distribution. Stock fell 14.78% after FY26 guidance disappointment. Bearish technical indicators and no significant hedge fund or insider trading activity.
In Q4 2025, revenue increased by 33.96% YoY to $10.4 million. Net income improved by 44.56% YoY but remains negative at -$7.79 million. EPS increased by 35% YoY to -$0.27. Gross margin improved slightly to 61.52%.
B. Riley maintains a Buy rating with a raised price target of $20 from $18, citing strong revenue growth and potential FDA approvals. However, recent adjustments to guidance and regulatory challenges have created near-term uncertainty.
